In 2014, about 76 100 new melanomas will be diagnosed, and an estimated 9710 persons will die (about 6470 men and 3240 women).1 Patients with melanoma in situ, stage 0, have a 5-year survival rate of 99% when treated with excision, whereas those with melanoma limited to the skin and with a tumor thickness of 2.01 to 4.0 mm, stage II B, have a 5-year survival rate of about 57%. Patients with metastatic melanoma, stage IV, have a 5-year survival rate of 15% to 20%. Despite newly available targeted agents, systemic therapies rarely lead to cures. These sizable survival differences illustrate the need for early detection of melanoma; early detection of primary melanomas followed by surgical excision remains critical.
Robinson JK. Role of Sildenafil in Melanoma Incidence and Mortality. JAMA Intern Med. 2014;174(6):970–971. doi:10.1001/jamainternmed.2014.157
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: